Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

BOTHELL, WA and VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone. The manuscript was published in the September 20, 2010 issue of the journal.

"The survival analysis provides a strong suggestion of clinical benefit with a hazard ratio consistent with a 50% reduction in the rate of death favoring custirsen treatment," said Dr. Kim Chi, Principal Investigator and medical oncologist at BC Cancer Agency. "These data provide the foundation and rationale for the upcoming SYNERGY Phase 3 trial evaluating custirsen in approximately 800 men with metastatic CRPC."

The study investigators concluded custirsen in combination with docetaxel was well tolerated. Furthermore, they noted that adverse events associated with custirsen, including lymphopenia, rigors and fever have been reported with other antisense therapeutics.

Analysis of trial results also showed:

- The observed survival benefit was attributed to the custirsen treatment rather than duration of docetaxel treatment or administration of subsequent therapies; - Fewer patients discontinued study therapy because of disease progression when custirsen was given (18% in custirsen plus docetaxel arm versus 39% in docetaxel arm), resulting in a greater number of treatment cycles administered (median of 9 cycles in custirsen plus docetaxel arm versus 7 cycles in docetaxel arm); - Statistically significant declines in serum clus
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... (PRWEB) May 22, 2013 ... sound therapy for tinnitus treatment. AudioNotch is pleased ... . With clinic locations in both British Columbia ... of audiology and hearing services. AudioNotch's tinnitus treatment ... , Upon entering a Destination Hearing clinic, patients ...
(Date:5/22/2013)... PA (PRWEB) May 22, 2013 Envera ... as Fermentation Manager. Mr. McErlean has an extensive ... of leadership positions throughout his career. , ... are very pleased to have Mike join our team”. ... installed large scale fermentation and downstream processing ...
(Date:5/21/2013)... 2013 First patients dosed with ... bromide designed using Prosonix, particle engineering platform ... of inhaled Respiratory Medicines by Design , has ... will assess its effect on lung function and the ... moderate to severe chronic obstructive pulmonary disease (COPD). The ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Through science ... and funds for lab equipment, 25 organizations will continue ... importance of optics and photonics in daily life with ... , The organizations, located in 10 countries, are the ... be awarded by SPIE, the international society for ...
Breaking Biology Technology:AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Envera Appoints Michael McErlean Fermentation Manager 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3
... 26 Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ... has received final approval from the,United States (U.S.) ... Drug Application (ANDA) for albuterol sulfate inhalation solution ... has been awarded 180,days of marketing exclusivity for ...
... Pharmaceuticals,Inc. (Nasdaq: ARNA ) today announced that ... inaugural companies in the new NASDAQ(R) NeuroInsights(R) Neurotech,Index. ... index designed to track,the performance of selected neurotechnology ... major U.S. stock exchanges. The NASDAQ NeuroInsights,Neurotech Index ...
... Coggins to Continue as President and CSO, ... Ltd., a privately held biotechnology company developing,first-in-class Leukocyte ... the appointment of Jack M. Anthony to Chief,Executive ... position of,CEO will continue as President and assume ...
Cached Biology Technology:Watson Receives FDA Approval for Generic Accuneb(R) 2Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 2Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 3Osprey Pharmaceuticals Names Jack M. Anthony as CEO 2Osprey Pharmaceuticals Names Jack M. Anthony as CEO 3
(Date:5/22/2013)... NEW YORK, May 22, 2013. Plastic additives known ... just about everywhere: They turn up in flooring, ... andaccording to the Centers for Disease Control and ... harmless, phthalates have come under increasing scrutiny. A ... phthalates (which can leech from packaging and mix ...
(Date:5/21/2013)... When infections occur in the body, stem cells ... multiplying and differentiating into mature immune cells that ... inflammation can deplete these cell populations, potentially leading ... as cancer. Now, a team of researchers led ... (Caltech) has found that, in mouse models, the ...
(Date:5/21/2013)... health stores, phosphatidylserine is a natural food supplement ... improve cognition and slow memory loss, it,s a ... Now a team headed by Prof. Gil Ast ... Department of Human Molecular Genetics have ... of genes involved in degenerative brain disorders, including ...
Breaking Biology News(10 mins):Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Keeping stem cells strong 2Common food supplement fights degenerative brain disorders 2
... May 11, 2010 For the first time in ... two-year decline in preterm birth rates, indicating that strategies implemented over ... the March of Dimes. "In 2003, we began a national ... baby deserves a healthy start in life," said Dr. Jennifer L. ...
... 2010 -- Investigators from around the country came to ... to share their knowledge of the burgeoning young field ... off proteins and have been implicated in viral infection, ... "The discovery that small RNAs could shut down ...
... May 11, 2010 -- Cancer uses devious means to ... way tumors express anti-cell death (anti-apoptotic) proteins to resist ... Medical Research Institute (Sanford-Burnham) has made two recent discoveries ... current treatments more effective. In a paper published ...
Cached Biology News:Federal report finds early births decline in most categories 2Researchers share insights into RNA 2Cancer: Trapping the escape artist 2
... ReadySub-Cell GT cell and PowerPac basic power supply ... nucleic acids in agarose gels. The mini format ... and electrodes, and leveling bubble. The PowerPac basic ... of 10-300 V, 4-400 mA, and 75 W. ...
... This CE-based system provides clear advantages ... (viral load, gene expression), mutation analysis, ... easy-to-use system with microplate connectivity is ... and quality control. The P/ACE ...
The imaging screen-K (Kodak), tritium, is a 20 x 25 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The optional fixed lens, 105 mm, is for use with the VersaDoc imaging systems for imaging small samples at high resolution....
Biology Products: